# US 2017/0281805 A1 · Novel anthranilic acid derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281805 A1
- Document ID: US20170281805A1
- Status: Published application
- Kind: A1
- Application number: 15/510,293
- Filed: 2015-09-21
- Published: 2017-10-05
- Earliest claimed: 2014-10-03
- Inventors: Divya MAHESHWARI; Uday Balkrishna GOKHALE
- Web page: https://patentgrep.com/patent/US20170281805A1

## CPC

- A61K 51/0455: {having six-membered rings with one nitrogen as the only ring hetero atom}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention is directed to a novel compound of Formula 1 wherein the radiolabeled compound of Formula 1 is capable of being used as a radiotracer in PET imaging of a targeted localized tissue and targeted radionuclide therapy of one or more conditions that may be regulated or normalized via inhibition of transporter such as Pgp, BCRP or MRP I. The novel compounds of Formula 1 can also be used as substrates for binding with one or more ABC transporters. In particular, the present invention aids in diagnosis and therapeutic treatment of MDR disorders in all forms of cancers and neurological disorders of the central nervous system. The present invention further provides methods of preparation of compounds of Formula 1 and novel intermediates used in the preparation of compounds of Formula 1.

## Claims

### Claim 1

A compound of Formula 1,
or a pharmaceutically acceptable salt thereof; wherein,
R1 is methoxy;
R2 is —(CH2)m wherein X is halogen or a radioactive isotope;
R3 is selected from H or —C1-C6 alkyl;
R4 is selected from H, —O—C1-C6 alkyl or —C1-C6 alkyl;
R5 is selected from H, —C1-C6 alkyl or —C1-C6 alkoxy;
Q is selected from a group consisting of a direct bond, O, S, —S—(CH2)m or —O—(CH2)m wherein m is an integer selected from 1, 2, 3, 4, 5 or 6;
“” is either a single bond or double bond;
R6 is selected from the group consisting of aryl, 5-10 membered heteroaryl and 3-14 membered heterocyclyl ring;
R7 and R8 are same or different and are independently selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy, halogen, phenyl, —NHOH, nitro, a group N(R10R11) or a group SR11 wherein R10 and R11 are independently selected from H or C1-C6 alkyl; or R7 and R8, when attached on adjacent carbon atoms, join together with the carbon atoms to which they are attached, to form a benzene ring or a methylenedioxy substituent;
n is 0 or an integer selected from 1, 2, 3, 4, 5 or 6; and
p is 0 or an integer selected from 1, 2 or 3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X is a halogen selected from chlorine, bromine, fluorine or iodine.

### Claim 3 (depends on 1)

The compound of claim 1, wherein X is a radioactive nuclide selected from 15O, 13N, 11C, 18F, 68Ga, 89Zr, 94Tc, 99mTc, 201TI or 123I.

### Claim 4 (depends on 1)

The compound of claim 1, wherein
R6 is an unsubstituted or substituted aryl ring selected from six to ten membered aromatic ring wherein the substituent is one or more groups selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, halogen and —OH, which aryl ring is optionally fused to one or two rings independently selected from the group consisting of cycloalkyl, aryl and substituted versions thereof wherein the substituent is one or more groups selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, halogen, haloalkyl and —OH; or
R6 is an unsubstituted or substituted 5-10 membered heteroaryl ring having one to five heteroatoms independently selected from N, O, S or P, wherein the substituent is one or more groups selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, halogen and —OH, which heteroaryl ring is optionally fused to one or two rings independently selected from the group consisting of aryl, cycloalkyl, heterocyclyl, monocyclic heteroaryl and substituted versions thereof wherein the substituent is one or more groups selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, halogen, haloalkyl or —OH; or
R6 is an unsubstituted or substituted 3-14 membered heterocyclyl ring, fully or partially unsaturated, having one to five heteroatoms independently selected from N, O, S or P, wherein the substituent is one or more groups selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, halogen and —OH, which heterocyclyl ring is optionally fused to one or two rings independently selected from the group consisting of an aryl ring, a cycloalkyl ring, a heteroaryl ring, heterocyclyl ring and substituted versions thereof wherein the substituent is one or more groups selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, halogen, haloalkyl or —OH.

### Claim 5 (depends on 1)

The compound of claim 1, wherein
R6 is an aryl ring selected from the group consisting of phenyl, naphthyl and substituted versions thereof wherein the substituent is one or more groups selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, halogen and —OH; or
R6 is a 5-10 membered heteroaryl ring selected from the group consisting of oxazolyl, imidazolyl, pyrrolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, fhiazolyl, oxadiazolyl, quinolinyl, benzoimidazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, thienyl, isoxazolyl, triazinyl, furanyl, benzofuranyl, indolyl, benzothiazolyl, benzoxazolyl, imidazo[1,2-a]pyrimidine, imidazo[1,2-a]pyrazine, tetrahydroquinoline and substituted versions thereof wherein the substituent is one or more groups selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, halogen, haloalkyl and —OH; or
R6 is a 3-14 membered heterocyclyl ring selected from the group consisting of morpholinyl, oxazolidinyl, tetrahydroiuranyl, tetrahydroquinolinyl, dihydrofuranyl, dihydropyridinyl, dihydroisooxazolyl, dihydrobenzofuryl, azabicyclohexyl, dihydroindonyl, piperidinyl and piperazinyl and substituted versions thereof wherein the substituent is one or more groups selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, halogen, haloalkyl and —OH.

### Claim 6

The compound of formula 1, wherein R6 is selected from the group consisting

### Claim 7

The compound of formula 1, wherein R6 is

### Claim 8

A compound of Formula 1a

### Claim 9

A compound of Formula 1b

### Claim 10 (depends on 1)

A process for preparation of compound of formula 1,
comprising the steps of: reacting a compound of formula 2
wherein R1, R3, R4, R5, R6, R7, R8, Q, “”, n and p are each as defined in claim 1;
with L-R2, wherein L is a leaving group and R2 is as defined in claim 1, under conditions effective to produce formula 1.

### Claim 11 (depends on 10)

The process of claim 10, wherein the compound of formula 2 is reacted with L-R2 in presence of cesium carbonate and DMF.

### Claim 12 (depends on 10)

The process of claim 10, wherein the leaving group L is iodo.

### Claim 13 (depends on 1)

A method for inhibiting adenosine triphosphate (ATP) transporter function, the method comprising administering to a mammal an ATP transporter inhibiting amount of a compound of Formula 1 according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

A method for detecting multi drug resistance protein 1 (MDR1)/P-glycoprotein (P-gp) mediated resistance, the method comprising introducing into a mammal harbouring a tumour or malignant growth a detectable quantity of a radiolabeled compound of Formula 1 according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

A method for detecting or imaging a site of targeted localized tissue, the method comprising introducing into a mammal a detectable quantity of a radiolabeled compound of Formula 1 according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the targeted localized tissue is a tumour or cell growth/proliferation.

### Claim 17 (depends on 14)

The method of claim 14, wherein the compound of formula 1 is labeled with a radionuclide selected from 15O, 13N, 11C, 18F, 68Ga, 89Zr, 94Tc, 99mTc, 201TI or 123I.

### Claim 18

A pharmaceutical composition comprising a compound of formula 1 and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 15)

The method of claim 15, wherein the compound of formula 1 is labeled with a radionuclide selected from 15O, 13N, 11C, 18F, 68Ga, 89Zr, 94Tc, 99mTc, 201TI or 123I.
